Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT00568984
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 131
- Registration Number
- NCT00568074
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00567775
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Glostrup, Denmark
Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
Phase 4
Completed
- Conditions
- Growth Hormone DisorderGrowth Hormone Deficiency in Children
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 176
- Registration Number
- NCT00567385
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Altunizade-Istanbul, Turkey
Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 126
- Registration Number
- NCT00564668
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women
Phase 3
Terminated
- Conditions
- Urinary InfectionsMenopause
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6
- Registration Number
- NCT00560924
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
Phase 3
Completed
- Conditions
- Foetal Growth ProblemSmall for Gestational Age
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 160
- Registration Number
- NCT00557336
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT00542620
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 296
- Registration Number
- NCT00537303
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Rugby, United Kingdom
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT00537277
© Copyright 2025. All Rights Reserved by MedPath